47 results on '"DeBerardinis R"'
Search Results
2. Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction
- Author
-
Cetinbas, N, Daugaard, M, Mullen, A R, Hajee, S, Rotblat, B, Lopez, A, Li, A, DeBerardinis, R J, and Sorensen, P H
- Published
- 2015
- Full Text
- View/download PDF
3. 635 Intraoperative 13C-glucose tracing and metabolomics of patient melanoma tumors reveal metabolic features associated with aggressive melanomas
- Author
-
Gill, J.G., Rao, A., Walsdorf, R., Snyman, M., Wix, S., Brown, A., Gard, G., Kim, J., Patricio, J. Santos, Zacharias, L., Solmonson, A., Tillman, B., Sharma, R., Vandergriff, T., Mathews, T., Cai, L., and DeBerardinis, R.
- Published
- 2024
- Full Text
- View/download PDF
4. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death
- Author
-
Kucejova, B, Sunny, N E, Nguyen, A D, Hallac, R, Fu, X, Peña-Llopis, S, Mason, R P, DeBerardinis, R J, Xie, X-J, DeBose-Boyd, R, Kodibagkar, V D, Burgess, S C, and Brugarolas, J
- Published
- 2011
- Full Text
- View/download PDF
5. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
- Author
-
DeBerardinis, R J and Cheng, T
- Published
- 2010
- Full Text
- View/download PDF
6. 669 In vivo characterization of melanoma metabolism in human patients through intraoperative [U-13C] glucose infusions
- Author
-
Gill, J.G., primary, Rao, A., additional, Player, D., additional, Sharma, R., additional, Tillman, B., additional, Huth, J., additional, Homsi, J., additional, Vandergriff, T., additional, and Deberardinis, R., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes
- Author
-
Elia, J, Gai, X, Xie, H M, Perin, J C, Geiger, E, Glessner, J T, Dʼarcy, M, deBerardinis, R, Frackelton, E, Kim, C, Lantieri, F, Muganga, B M, Wang, L, Takeda, T, Rappaport, E F, Grant, S FA, Berrettini, W, Devoto, M, Shaikh, T H, Hakonarson, H, and White, P S
- Published
- 2010
- Full Text
- View/download PDF
8. Metabolomics Profiling of Mouse Oral Squamous Cell Carcinoma (AT 84) after Irradiation Under Normoxia and Hypoxia Conditions
- Author
-
Zhang, Y., primary, Vu, H., additional, Zacharias, L., additional, Sishc, B.J., additional, Saha, D., additional, Deberardinis, R., additional, and Story, M.D., additional
- Published
- 2019
- Full Text
- View/download PDF
9. MS32.01 Genetic Mouse Models (GEMMS)
- Author
-
Mollaoglu, G., primary, Chalishazar, M., additional, Huang, F., additional, Guthrie, M., additional, Bohm, S., additional, Br€Agelmann, J., additional, Sen, T., additional, Byers, L., additional, Johnson, J., additional, Wechsler-Reya, R., additional, Gazdar, A., additional, Deberardinis, R., additional, Sos, M., additional, and Oliver, T., additional
- Published
- 2018
- Full Text
- View/download PDF
10. 639 Metabolic reprogramming maintains skin integrity in the absence of glucose transport and identifies a therapeutic vulnerability in psoriasiform hyperplasia
- Author
-
Zhang, Z., primary, Zi, Z., additional, Lee, E., additional, Zhao, J., additional, South, A.P., additional, Chong, B.F., additional, Vandergriff, T., additional, Hosler, G.A., additional, Scherer, P., additional, Mettlen, M., additional, Deberardinis, R., additional, and Wang, R., additional
- Published
- 2018
- Full Text
- View/download PDF
11. Genetic Mouse Models (GEMMS)
- Author
-
Mollaoglu, G., Chalishazar, M., Huang, F., Guthrie, M., Bohm, S., Breagelmann, J., Sen, T., Byers, L., Johnson, J., Wechsler-Reya, R., Gazdar, A., Deberardinis, R., Sos, M., Oliver, T., Mollaoglu, G., Chalishazar, M., Huang, F., Guthrie, M., Bohm, S., Breagelmann, J., Sen, T., Byers, L., Johnson, J., Wechsler-Reya, R., Gazdar, A., Deberardinis, R., Sos, M., and Oliver, T.
- Published
- 2018
12. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- Author
-
Galluzzi, Lorenzo, Vitale, Ilio, Aaronson, S. A., Abrams, J. M., Adam, Dieter, Agostinis, Patrizia, Alnemri, E. S., Altucci, Lucia, Amelio, Ivano, Andrews, D. W., Annicchiarico-Petruzzelli, Margherita, Antonov, A. V., Arama, Eli, Baehrecke, E. H., Barlev, N. A., Bazan, N. G., Bernassola, Francesca, Bertrand, M. J. M., Bianchi, Katiuscia, Blagosklonny, M. V., Blomgren, Kla, Borner, Christoph, Boya, Patricia, Brenner, Catherine, Campanella, Michelangelo, Candi, Eleonora, Carmona-Gutierrez, Didac, Cecconi, Francesco, Chan, F. K. -M., Chandel, N. S., Cheng, E. H., Chipuk, J. E., Cidlowski, J. A., Ciechanover, Aaron, Cohen, G. M., Conrad, Marcu, Cubillos-Ruiz, J. R., Czabotar, P. E., D’Angiolella, Vincenzo, Dawson, T. M., Dawson, V. L., de Laurenzi, Vincenzo, De Maria Marchiano, Ruggero, Debatin, Klaus-Michael, Deberardinis, R. J., Deshmukh, Mohanish, Di Daniele, Nicola, Di Virgilio, Francesco, Dixit, V. M., Dixon, S. J., Duckett, C. S., Dynlacht, B. D., El-Deiry, W. S., Elrod, J. W., Fimia, Gian Maria, Fulda, Simone, García-Sáez, A. J., Garg, A. D., Garrido, Carmen, Gavathiotis, Evripidi, Golstein, Pierre, Gottlieb, Eyal, Green, D. R., Greene, L. A., Gronemeyer, Hinrich, Gross, Atan, Hajnoczky, Gyorgy, Hardwick, J. M., Harris, I. S., Hengartner, M. O., Hetz, Claudio, Ichijo, Hidenori, Jäättelä, Marja, Joseph, Bertrand, Jost, P. J., Juin, P. P., Kaiser, W. J., Karin, Michael, Kaufmann, Thoma, Kepp, Oliver, Kimchi, Adi, Kitsis, R. N., Klionsky, D. J., Knight, R. A., Kumar, Sharad, Lee, S. W., Lemasters, J. J., Levine, Beth, Linkermann, Andrea, Lipton, S. A., Lockshin, R. A., López-Otín, Carlo, Lowe, S. W., Luedde, Tom, Lugli, Enrico, Macfarlane, Marion, Madeo, Frank, Malewicz, Michal, Malorni, Walter, Manic, Gwenola, Marine, Jean-Christophe, Martin, S. J., Martinou, Jean-Claude, Medema, Jan Paul, Mehlen, Patrick, Meier, Pascal, Melino, Sonia, Miao, E. A., Molkentin, J. D., Moll, U. M., Muñoz-Pinedo, Cristina, Nagata, Shigekazu, Nuñez, Gabriel, Oberst, Andrew, Oren, Moshe, Overholtzer, Michael, Pagano, Michele, Panaretakis, Theochari, Pasparakis, Manoli, Penninger, J. M., Pereira, D. M., Pervaiz, Shazib, Peter, M. E., Piacentini, Mauro, Pinton, Paolo, Prehn, J. H. M., Puthalakath, Hamsa, Rabinovich, G. A., Rehm, Marku, Rizzuto, Rosario, Rodrigues, C. M. P., Rubinsztein, D. C., Rudel, Thoma, Ryan, K. M., Sayan, Emre, Scorrano, Luca, Shao, Feng, Shi, Yufang, Silke, John, Simon, Hans-Uwe, Sistigu, Antonella, Stockwell, B. R., Strasser, Andrea, Szabadkai, Gyorgy, Tait, S. W. G., Tang, Daolin, Tavernarakis, Nektario, Thorburn, Andrew, Tsujimoto, Yoshihide, Turk, Bori, Vanden Berghe, Tom, Vandenabeele, Peter, Vander Heiden, M. G., Villunger, Andrea, Virgin, H. W., Vousden, K. H., Vucic, Domagoj, Wagner, E. F., Walczak, Henning, Wallach, David, Wang, Ying, Wells, J. A., Wood, Will, Yuan, Junying, Zakeri, Zahra, Zhivotovsky, Bori, Zitvogel, Laurence, Melino, Gerry, Kroemer, Guido, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Sistigu, Antonella (ORCID:0000-0002-2528-1238), Galluzzi, Lorenzo, Vitale, Ilio, Aaronson, S. A., Abrams, J. M., Adam, Dieter, Agostinis, Patrizia, Alnemri, E. S., Altucci, Lucia, Amelio, Ivano, Andrews, D. W., Annicchiarico-Petruzzelli, Margherita, Antonov, A. V., Arama, Eli, Baehrecke, E. H., Barlev, N. A., Bazan, N. G., Bernassola, Francesca, Bertrand, M. J. M., Bianchi, Katiuscia, Blagosklonny, M. V., Blomgren, Kla, Borner, Christoph, Boya, Patricia, Brenner, Catherine, Campanella, Michelangelo, Candi, Eleonora, Carmona-Gutierrez, Didac, Cecconi, Francesco, Chan, F. K. -M., Chandel, N. S., Cheng, E. H., Chipuk, J. E., Cidlowski, J. A., Ciechanover, Aaron, Cohen, G. M., Conrad, Marcu, Cubillos-Ruiz, J. R., Czabotar, P. E., D’Angiolella, Vincenzo, Dawson, T. M., Dawson, V. L., de Laurenzi, Vincenzo, De Maria Marchiano, Ruggero, Debatin, Klaus-Michael, Deberardinis, R. J., Deshmukh, Mohanish, Di Daniele, Nicola, Di Virgilio, Francesco, Dixit, V. M., Dixon, S. J., Duckett, C. S., Dynlacht, B. D., El-Deiry, W. S., Elrod, J. W., Fimia, Gian Maria, Fulda, Simone, García-Sáez, A. J., Garg, A. D., Garrido, Carmen, Gavathiotis, Evripidi, Golstein, Pierre, Gottlieb, Eyal, Green, D. R., Greene, L. A., Gronemeyer, Hinrich, Gross, Atan, Hajnoczky, Gyorgy, Hardwick, J. M., Harris, I. S., Hengartner, M. O., Hetz, Claudio, Ichijo, Hidenori, Jäättelä, Marja, Joseph, Bertrand, Jost, P. J., Juin, P. P., Kaiser, W. J., Karin, Michael, Kaufmann, Thoma, Kepp, Oliver, Kimchi, Adi, Kitsis, R. N., Klionsky, D. J., Knight, R. A., Kumar, Sharad, Lee, S. W., Lemasters, J. J., Levine, Beth, Linkermann, Andrea, Lipton, S. A., Lockshin, R. A., López-Otín, Carlo, Lowe, S. W., Luedde, Tom, Lugli, Enrico, Macfarlane, Marion, Madeo, Frank, Malewicz, Michal, Malorni, Walter, Manic, Gwenola, Marine, Jean-Christophe, Martin, S. J., Martinou, Jean-Claude, Medema, Jan Paul, Mehlen, Patrick, Meier, Pascal, Melino, Sonia, Miao, E. A., Molkentin, J. D., Moll, U. M., Muñoz-Pinedo, Cristina, Nagata, Shigekazu, Nuñez, Gabriel, Oberst, Andrew, Oren, Moshe, Overholtzer, Michael, Pagano, Michele, Panaretakis, Theochari, Pasparakis, Manoli, Penninger, J. M., Pereira, D. M., Pervaiz, Shazib, Peter, M. E., Piacentini, Mauro, Pinton, Paolo, Prehn, J. H. M., Puthalakath, Hamsa, Rabinovich, G. A., Rehm, Marku, Rizzuto, Rosario, Rodrigues, C. M. P., Rubinsztein, D. C., Rudel, Thoma, Ryan, K. M., Sayan, Emre, Scorrano, Luca, Shao, Feng, Shi, Yufang, Silke, John, Simon, Hans-Uwe, Sistigu, Antonella, Stockwell, B. R., Strasser, Andrea, Szabadkai, Gyorgy, Tait, S. W. G., Tang, Daolin, Tavernarakis, Nektario, Thorburn, Andrew, Tsujimoto, Yoshihide, Turk, Bori, Vanden Berghe, Tom, Vandenabeele, Peter, Vander Heiden, M. G., Villunger, Andrea, Virgin, H. W., Vousden, K. H., Vucic, Domagoj, Wagner, E. F., Walczak, Henning, Wallach, David, Wang, Ying, Wells, J. A., Wood, Will, Yuan, Junying, Zakeri, Zahra, Zhivotovsky, Bori, Zitvogel, Laurence, Melino, Gerry, Kroemer, Guido, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), and Sistigu, Antonella (ORCID:0000-0002-2528-1238)
- Abstract
Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process. As we provide molecularly oriented definitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe, we discuss the utility of neologisms that refer to highly specialized instances of these processes. The mission of the NCCD is to provide a widely accepted nomenclature on cell death in support of the continued development of the field.
- Published
- 2018
13. Erratum: Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes
- Author
-
Elia, J, Gai, X, Xie, H M, Perin, J C, Geiger, E, Glessner, J T, D'arcy, M, deBerardinis, R, Frackelton, E, Kim, C, Lantieri, F, Muganga, B M, Wang, L, Takeda, T, Rappaport, E F, Grant, S F A, Berrettini, W, Devoto, M, Shaikh, T H, Hakonarson, H, and White, P S
- Published
- 2010
- Full Text
- View/download PDF
14. 725 Epidermal deletion of Glut1 highlights essential roles for glucose metabolism in wound healing and the response to UVB irradiation
- Author
-
Zhang, Z., primary, Zi, Z., additional, Lee, E.E., additional, Yue, Y., additional, Vandergriff, T., additional, Abel, E., additional, DeBerardinis, R., additional, and Wang, R.C., additional
- Published
- 2017
- Full Text
- View/download PDF
15. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
- Author
-
Moore, Z, primary, Chakrabarti, G, additional, Luo, X, additional, Ali, A, additional, Hu, Z, additional, Fattah, F J, additional, Vemireddy, R, additional, DeBerardinis, R J, additional, Brekken, R A, additional, and Boothman, D A, additional
- Published
- 2015
- Full Text
- View/download PDF
16. Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition
- Author
-
Jiang, L, primary, Xiao, L, additional, Sugiura, H, additional, Huang, X, additional, Ali, A, additional, Kuro-o, M, additional, Deberardinis, R J, additional, and Boothman, D A, additional
- Published
- 2014
- Full Text
- View/download PDF
17. Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction
- Author
-
Cetinbas, N, primary, Daugaard, M, additional, Mullen, A R, additional, Hajee, S, additional, Rotblat, B, additional, Lopez, A, additional, Li, A, additional, DeBerardinis, R J, additional, and Sorensen, P H, additional
- Published
- 2014
- Full Text
- View/download PDF
18. METABOLIC PATHWAYS
- Author
-
Locasale, J. W., primary, Melman, T., additional, Song, S. S., additional, Yang, X., additional, Swanson, K. D., additional, Cantley, L. C., additional, Asara, J. M., additional, Wong, E. T., additional, Adams, S., additional, Braidy, N., additional, Teo, C., additional, Guillemin, G., additional, Philippe, M., additional, Carole, C., additional, David, T., additional, Eric, G., additional, Isabelle, N.-M., additional, de Paula Andre, M., additional, Marylin, B., additional, Olivier, C., additional, L'Houcine, O., additional, Dominique, F.-B., additional, Leukel, P., additional, Seliger, C., additional, Vollmann, A., additional, Jachnik, B., additional, Bogdahn, U., additional, Hau, P., additional, Liu, X., additional, Kumar, V. S., additional, McPherson, C. M., additional, Chow, L., additional, Kendler, A., additional, Dasgupta, B., additional, Piya, S., additional, White, E., additional, Klein, S., additional, Jiang, H., additional, Lang, F., additional, Alfred Yung, W. K., additional, Gomez-Manzano, C., additional, Fueyo, J., additional, Vartanian, A., additional, Guha, A., additional, Fenton, K. E., additional, Abdelwahab, M., additional, Scheck, A. C., additional, Guo, D., additional, Reinitz, F., additional, Youssef, M., additional, Hong, C., additional, Nathanson, D., additional, Akhavan, D., additional, Kuga, D., additional, Amzajerdi, A. N., additional, Soto, H., additional, Zhu, S., additional, Babic, I., additional, Iwanami, A., additional, Tanaka, K., additional, Gini, B., additional, DeJesus, J., additional, Lisiero, D. D., additional, Huang, T., additional, Prins, R., additional, Wen, P., additional, Robbins, H. I., additional, Prados, M., additional, DeAngelis, L., additional, Mellinghoff, I., additional, Mehta, M., additional, James, C. D., additional, Chakravarti, A., additional, Cloughesy, T., additional, Tontonoz, P., additional, Mischel, P., additional, Phillips, J., additional, Mukherjee, J., additional, Cowdrey, C., additional, Wiencke, J., additional, Pieper, R. O., additional, Bachoo, R., additional, Marin-Valencia, I., additional, Cho, S., additional, Rakheja, D., additional, Hatanpaa, K., additional, Mashimo, T., additional, Vemireddy, V., additional, Kapur, P., additional, Good, L., additional, Sun, X., additional, Pascual, J., additional, Takahashi, M., additional, Togao, O., additional, Raisanen, J., additional, Maher, E. A., additional, DeBerardinis, R., additional, Malloy, C., additional, Choi, C., additional, Mathews, D., additional, Madden, C., additional, Mickey, B., additional, Zheng, S., additional, Ronen, S., additional, Park, I., additional, Jalbert, L. E., additional, Ito, M., additional, Ozawa, T., additional, Phillips, J. J., additional, Vigneron, D. B., additional, Ronen, S. M., additional, and Nelson, S. J., additional
- Published
- 2011
- Full Text
- View/download PDF
19. MEDICAL AND NEURO-ONCOLOGY
- Author
-
Prithviraj, G. K., primary, Sommers, S. R., additional, Jump, R. L., additional, Halmos, B., additional, Chambless, L. B., additional, Parker, S. L., additional, Hassam-Malani, L., additional, McGirt, M. J., additional, Thompson, R. C., additional, Hunter, K., additional, Chamberlain, M. C., additional, Le, E. M., additional, Lee, E. L. T., additional, Sadighi, Z. S., additional, Pearlman, M. L., additional, Slopis, J. M., additional, Vats, T. S., additional, Khatua, S., additional, DeVito, N. C., additional, Yu, M., additional, Chen, R., additional, Pan, E., additional, Cloughesy, T., additional, Raizer, J., additional, Drappatz, J., additional, Gerena-Lewis, M., additional, Rogerio, J., additional, Yacoub, S., additional, Desjardin, A., additional, Groves, M. D., additional, DeGroot, J., additional, Loghin, M., additional, Conrad, C. A., additional, Hess, K., additional, Ni, J., additional, Ictech, S., additional, Yung, W. A., additional, Porter, A. B., additional, Dueck, A. C., additional, Karlin, N. J., additional, Olson, J., additional, Silber, J., additional, Reiner, A. S., additional, Panageas, K. S., additional, Iwamoto, F. M., additional, Cloughesy, T. F., additional, Aldape, K. D., additional, Rivera, A. L., additional, Eichler, A. F., additional, Louis, D. N., additional, Paleologos, N. A., additional, Fisher, B. J., additional, Ashby, L. S., additional, Cairncross, J. G., additional, Roldan, G. B., additional, Wen, P. Y., additional, Ligon, K. L., additional, Shiff, D., additional, Robins, H. I., additional, Rocque, B. G., additional, Mason, W. P., additional, Weaver, S. A., additional, Green, R. M., additional, Kamar, F. G., additional, Abrey, L. E., additional, DeAngelis, L. M., additional, Jhanwar, S. C., additional, Rosenblum, M. K., additional, Lassman, A. B., additional, Cachia, D., additional, Alderson, L., additional, Moser, R., additional, Smith, T., additional, Yunus, S., additional, Saito, K., additional, Mukasa, A., additional, Narita, Y., additional, Tabei, Y., additional, Shinoura, N., additional, Shibui, S., additional, Saito, N., additional, Flechl, B., additional, Ackerl, M., additional, Sax, C., additional, Dieckmann, K., additional, Crevenna, R., additional, Widhalm, G., additional, Preusser, M., additional, Marosi, C., additional, Ay, C., additional, Dunkler, D., additional, Pabinger, I., additional, Zielinski, C., additional, Belongia, M., additional, Jogal, S., additional, Schlingensiepen, K.-H., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V., additional, Parfenov, V., additional, Poverennova, I., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Mammoser, A. G., additional, Shonka, N. A., additional, de Groot, J. F., additional, Shibahara, I., additional, Sonoda, Y., additional, Kumabe, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Watanabe, M., additional, Ishioka, C., additional, Tominaga, T., additional, Silvani, A., additional, Gaviani, P., additional, Lamperti, E., additional, Botturi, A., additional, DiMeco, F., additional, Broggi, G., additional, Fariselli, L., additional, Solero, C. L., additional, Salmaggi, A., additional, Woyshner, E. A., additional, Shu, F., additional, Oh, Y. S., additional, Iganej, S., additional, Singh, G., additional, Vemuri, S. L., additional, Theeler, B. J., additional, Ellezam, B., additional, Gilbert, M. R., additional, Aoki, T., additional, Kobayashi, H., additional, Takano, S., additional, Nishikawa, R., additional, Nagane, M., additional, Muragaki, Y., additional, Sugiyama, K., additional, Kuratsu, J., additional, Matsutani, M., additional, Langford, L. A., additional, Puduvalli, V. K., additional, Shen, D., additional, Chen, Z.-p., additional, Zhang, J.-p., additional, Bedekar, D., additional, Rand, S., additional, Connelly, J., additional, Malkin, M., additional, Paulson, E., additional, Mueller, W., additional, Schmainda, K., additional, Gallego, O., additional, Benavides, M., additional, Segura, P. P., additional, Balana, C., additional, Gil, M., additional, Berrocal, A., additional, Reynes, G., additional, Garcia, J. L., additional, Murata, P., additional, Bague, S., additional, Quintana, M. J., additional, Vasishta, V. G., additional, Kobayashi, K., additional, Tanaka, M., additional, Tsuchiya, K., additional, Shiokawa, Y., additional, Bavle, A. A., additional, Ayyanar, K., additional, Prado, M. P., additional, Hess, K. R., additional, Liu, V., additional, de Groot, J., additional, Loghin, M. E., additional, Colman, H., additional, Levin, V. A., additional, Alfred Yung, W. K., additional, Hackney, J. R., additional, Palmer, C. A., additional, Markert, J. M., additional, Cure, J., additional, Riley, K. O., additional, Fathallah-Shaykh, H., additional, Nabors, L. B., additional, Saria, M. G., additional, Corle, C., additional, Hu, J., additional, Rudnick, J., additional, Phuphanich, S., additional, Mrugala, M. M., additional, Lee, L. K., additional, Fu, B. D., additional, Bota, D. A., additional, Kim, R. Y., additional, Brown, T., additional, Feely, H., additional, Hu, A., additional, Lee, J. W., additional, Carter, B., additional, Kesari, S., additional, Kong, X.-T., additional, Sparagana, S., additional, Belousova, E., additional, Jozwiak, S., additional, Korf, B., additional, Frost, M., additional, Kuperman, R., additional, Kohrman, M., additional, Witt, O., additional, Wu, J., additional, Flamini, R., additional, Jansen, A., additional, Curtalolo, P., additional, Thiele, E., additional, Whittemore, V., additional, De Vries, P., additional, Ford, J., additional, Shah, G., additional, Cauwel, H., additional, Edrich, P., additional, Sahmoud, T., additional, Franz, D., additional, Khasraw, M., additional, Brown, C., additional, Ashley, D. M., additional, Rosenthal, M. A., additional, Jiang, X., additional, Mou, Y. g., additional, Chen, Z. p., additional, Oh, M., additional, kim, E., additional, Chang, J., additional, Juratli, T. A., additional, Kirsch, M., additional, Schackert, G., additional, Krex, D., additional, Wang, M., additional, Stupp, R., additional, Hegi, M., additional, Jaeckle, K. A., additional, Armstrong, T. S., additional, Wefel, J. S., additional, Won, M., additional, Blumenthal, D. T., additional, Mahajan, A., additional, Schultz, C. J., additional, Erridge, S. C., additional, Brown, P. D., additional, Chakravarti, A., additional, Curran, W. J., additional, Mehta, M. P., additional, Hofland, K. F., additional, Hansen, S., additional, Sorensen, M., additional, Schultz, H., additional, Muhic, A., additional, Engelholm, S., additional, Ask, A., additional, Kristiansen, C., additional, Thomsen, C., additional, Poulsen, H. S., additional, Lassen, U. N., additional, Zalatimo, O., additional, Weston, C., additional, Zoccoli, C., additional, Glantz, M., additional, Rahmanuddin, S., additional, Shiroishi, M. S., additional, Cen, S. Y., additional, Jones, J., additional, Chen, T., additional, Pagnini, P., additional, Go, J., additional, Lerner, A., additional, Gomez, J., additional, Law, M., additional, Ram, Z., additional, Wong, E. T., additional, Gutin, P. H., additional, Bobola, M. S., additional, Alnoor, M., additional, Silbergeld, D. L., additional, Rostomily, R. C., additional, Silber, J. R., additional, Martha, N., additional, Jacqueline, S., additional, Thaddaus, G., additional, Daniel, P., additional, Hans, M., additional, Armin, M., additional, Eugen, T., additional, Gunther, S., additional, Hutterer, M., additional, Tseng, H.-M., additional, Zoccoli, C. M., additional, Patel, A., additional, Rizzo, K., additional, Sheehan, J. M., additional, Sumrall, A. L., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Reardon, D. A., additional, Friiedman, H. S., additional, Peters, K. B., additional, Taylor, L. P., additional, Stewart, M., additional, Blondin, N. A., additional, Baehring, J. M., additional, Foote, T., additional, Laack, N., additional, Call, J., additional, Hamilton, M. G., additional, Walling, S., additional, Eliasziw, M., additional, Easaw, J., additional, Shirsat, N. V., additional, Kundar, R., additional, Gokhale, A., additional, Goel, A., additional, Moiyadi, A. A., additional, Wang, J., additional, Mutlu, E., additional, Oyan, A., additional, Yan, T., additional, Tsinkalovsky, O., additional, Jacobsen, H. K., additional, Talasila, K. M., additional, Sleire, L., additional, Pettersen, K., additional, Miletic, H., additional, Andersen, S., additional, Mitra, S., additional, Weissman, I., additional, Li, X., additional, Kalland, K.-H., additional, Enger, P. O., additional, Sepulveda, J., additional, Belda, C., additional, Sitt, R., additional, Phishniak, L., additional, Bokstein, F., additional, Philippe, M., additional, Carole, C., additional, Andre, M. d. P., additional, Marylin, B., additional, Olivier, C., additional, L'Houcine, O., additional, Dominique, F.-B., additional, Isabelle, N.-M., additional, Frederic, F., additional, Stephane, F., additional, Henry, D., additional, Errico, M. A., additional, Kunschner, L. J., additional, Soffietti, R., additional, Trevisan, E., additional, Ruda, R., additional, Bertero, L., additional, Bosa, C., additional, Fabrini, M. G., additional, Lolli, I., additional, Jalali, R., additional, Julka, P. K., additional, Anand, A. K., additional, Bhavsar, D., additional, Singhal, N., additional, Naik, R., additional, John, S., additional, Mathew, B. S., additional, Thaipisuttikul, I., additional, Graber, J., additional, Shirinian, M., additional, Fontebasso, A. M., additional, Jacob, K., additional, Gerges, N., additional, Montpetit, A., additional, Nantel, A., additional, Albrecht, S., additional, Jabado, N., additional, Shah, K., additional, Di, K., additional, Linskey, M., additional, Thon, N., additional, Eigenbrod, S., additional, Kreth, S., additional, Lutz, J., additional, Tonn, J.-C., additional, Kretzschmar, H., additional, Peraud, A., additional, Kreth, F.-W., additional, Muggeri, A. D., additional, Alderuccio, J. P., additional, Diez, B. D., additional, Jiang, P., additional, Chao, Y., additional, Gallagher, M., additional, Kim, R., additional, Pastorino, S., additional, Fogal, V., additional, Rudnick, J. D., additional, Bresee, C., additional, Rogatko, A., additional, Sakowsky, S., additional, Franco, M., additional, Lim, S., additional, Lopez, A., additional, Yu, L., additional, Ryback, K., additional, Tsang, V., additional, Lill, M., additional, Steinberg, A., additional, Sheth, R., additional, Grimm, S., additional, Helenowski, I., additional, Rademaker, A., additional, Nunes, F. P., additional, Merker, V., additional, Jennings, D., additional, Caruso, P., additional, Muzikansky, A., additional, Stemmer-Rachamimov, A., additional, Plotkin, S., additional, Spalding, A. C., additional, Vitaz, T. W., additional, Sun, D. A., additional, Parsons, S., additional, Welch, M. R., additional, Omuro, A., additional, Beal, K., additional, Correa, D., additional, Chan, T., additional, DeAngelis, L., additional, Gavrilovic, I., additional, Nolan, C., additional, Hormigo, A., additional, Kaley, T., additional, Mellinghoff, I., additional, Grommes, C., additional, Panageas, K., additional, Reiner, A., additional, Barradas, R., additional, Abrey, L., additional, Gutin, P., additional, Lee, S. Y., additional, Slagle-Webb, B., additional, Glantz, M. J., additional, Connor, J. R., additional, Schlimper, C. A., additional, Schlag, H., additional, Stoffels, G., additional, Weber, F., additional, Krueger, D. A., additional, Care, M. M., additional, Holland, K., additional, Agricola, K., additional, Tudor, C., additional, Byars, A., additional, Franz, D. N., additional, Rice, L., additional, Chandler, J., additional, Levy, R., additional, Muro, K., additional, Nayak, L., additional, Norden, A. D., additional, Kaley, T. J., additional, Thomas, A. A., additional, Fadul, C. E., additional, Meyer, L. P., additional, Lallana, E. C., additional, Gilbert, M., additional, Aldape, K., additional, De Groot, J., additional, Conrad, C., additional, Levin, V., additional, Groves, M., additional, Chris, P., additional, Puduvalli, V., additional, Nagpal, S., additional, Feroze, A., additional, Recht, L., additional, Rangarajan, H. G., additional, Kieran, M. W., additional, Scott, R. M., additional, Lew, S. M., additional, Firat, S. Y., additional, Segura, A. D., additional, Jogal, S. A., additional, Kumthekar, P. U., additional, Grimm, S. A., additional, Avram, M., additional, Patel, J., additional, Kaklamani, V., additional, McCarthy, K., additional, Cianfrocca, M., additional, Gradishar, W., additional, Mulcahy, M., additional, Von Roenn, J., additional, Galanis, E., additional, Anderson, S. K., additional, Lafky, J. M., additional, Kaufmann, T. J., additional, Uhm, J. H., additional, Giannini, C., additional, Kumar, S. K., additional, Northfelt, D. W., additional, Flynn, P. J., additional, Buckner, J. C., additional, Omar, A. I., additional, Schiff, D., additional, Delios, A., additional, Jakubowski, A., additional, Melguizo-Gavilanes, I., additional, Qiao, W., additional, Wang, X., additional, Hashemi-Sadraei, N., additional, Bawa, H., additional, Rahmathulla, G., additional, Patel, M., additional, Elson, P., additional, Stevens, G., additional, Peereboom, D., additional, Vogelbaum, M., additional, Weil, R., additional, Barnett, G., additional, Ahluwalia, M. S., additional, Alvord, E. C., additional, Rockne, R. C., additional, Rockhill, J. K., additional, Rostomily, R., additional, Lai, A., additional, Wardlaw, J., additional, Spence, A. M., additional, Swanson, K. R., additional, Zadeh, G., additional, Alahmadi, H., additional, Wilson, J., additional, Gentili, F., additional, Beumer, J. J., additional, Wright, J., additional, Takebe, N., additional, Gaur, R., additional, Werner-Wasik, M., additional, Gupta, A. J., additional, Campos-Gines, A., additional, Le, K., additional, Arango, C., additional, Richards, M., additional, Landeros, M., additional, Juan, H., additional, Chang, J. H., additional, Kim, J. S., additional, Cho, J. H., additional, Seo, C. O., additional, Baldock, A. L., additional, Rockne, R., additional, Canoll, P., additional, Born, D., additional, Yagle, K., additional, Alexandru, D., additional, Bota, D., additional, Linskey, M. E., additional, Nabeel, S., additional, Raval, S. N., additional, Rosenow, J., additional, Bredel, M., additional, New, P. Z., additional, Plotkin, S. R., additional, Supko, J. G., additional, Curry, W. T., additional, Chi, A. S., additional, Gerstner, E. R., additional, Batchelor, T. T., additional, Hashemi, N., additional, Chao, S. T., additional, Weil, R. J., additional, Suh, J. H., additional, Vogelbaum, M. A., additional, Stevens, G. H., additional, Barnett, G. H., additional, Corwin, D., additional, Holdsworth, C., additional, Stewart, R., additional, Swanson, K., additional, Graber, J. J., additional, Anderson, A. R., additional, Jeyapalan, S., additional, Goldman, M., additional, Boxerman, J., additional, Donahue, J., additional, Elinzano, H., additional, Evans, D., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Oyelese, A., additional, Cielo, D., additional, Blitstein, M., additional, Dargush, M., additional, Santaniello, A., additional, Constantinou, M., additional, DiPetrillo, T., additional, Safran, H., additional, Halpin, C., additional, Barker, F. G., additional, Maher, E. A., additional, Ganji, S., additional, DeBerardinis, R., additional, Hatanpaa, K., additional, Rakheja, D., additional, Yang, X.-L., additional, Mashimo, T., additional, Raisanen, J., additional, Madden, C., additional, Mickey, B., additional, Malloy, C., additional, Bachoo, R., additional, Choi, C., additional, Ranjan, T., additional, Yono, N., additional, Han, S. J., additional, Sun, M., additional, Berger, M. S., additional, Aghi, M., additional, Gupta, N., additional, and Parsa, A. T., additional
- Published
- 2011
- Full Text
- View/download PDF
20. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
- Author
-
DeBerardinis, R J, primary and Cheng, T, additional
- Published
- 2009
- Full Text
- View/download PDF
21. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes
- Author
-
Elia, J, primary, Gai, X, additional, Xie, H M, additional, Perin, J C, additional, Geiger, E, additional, Glessner, J T, additional, D'arcy, M, additional, deBerardinis, R, additional, Frackelton, E, additional, Kim, C, additional, Lantieri, F, additional, Muganga, B M, additional, Wang, L, additional, Takeda, T, additional, Rappaport, E F, additional, Grant, S F A, additional, Berrettini, W, additional, Devoto, M, additional, Shaikh, T H, additional, Hakonarson, H, additional, and White, P S, additional
- Published
- 2009
- Full Text
- View/download PDF
22. Determination of L1 retrotransposition kinetics in cultured cells.
- Author
-
Ostertag, E M, Prak, E T, DeBerardinis, R J, Moran, J V, and Kazazian, H H
- Abstract
L1 retrotransposons are autonomous retroelements that are active in the human and mouse genomes. Previously, we developed a cultured cell assay that uses a neomycin phosphotransferase ( neo ) retrotransposition cassette to determine relative retrotransposition frequencies among various L1 elements. Here, we describe a new retrotransposition assay that uses an enhanced green fluorescent protein (EGFP) retrotransposition cassette to determine retrotransposition kinetics in cultured cells. We show that retrotransposition is not detected in cultured cells during the first 48 h post-transfection, but then proceeds at a continuous high rate for at least 16 days. We also determine the relative retrotransposition rates of two similar human L1 retrotransposons, L1(RP)and L1.3. L1(RP)retrotransposed in the EGFP assay at a rate of approximately 0.5% of transfected cells/day, approximately 3-fold higher than the rate measured for L1.3. We conclude that the new assay detects near real time retrotransposition in a single cell and is sufficiently sensitive to differentiate retrotransposition rates among similar L1 elements. The EGFP assay exhibits improved speed and accuracy compared to the previous assay when used to determine relative retrotransposition frequencies. Furthermore, the EGFP cassette has an expanded range of experimental applications.
- Published
- 2000
- Full Text
- View/download PDF
23. Human enteric defensins. Gene structure and developmental expression.
- Author
-
Mallow, E B, Harris, A, Salzman, N, Russell, J P, DeBerardinis, R J, Ruchelli, E, and Bevins, C L
- Abstract
Paneth cells, secretory epithelial cells of the small intestinal crypts, are proposed to contribute to local host defense. Both mouse and human Paneth cells express a collection of antimicrobial proteins, including members of a family of antimicrobial peptides named defensins. In this study, data from an anchored polymerase chain reaction (PCR) strategy suggest that only two defensin mRNA isoforms are expressed in the human small intestine, far fewer than the number expressed in the mouse. The two isoforms detected by this PCR approach were human defensin family members, HD-5 and HD-6. The gene encoding HD-6 was cloned and characterized. HD-6 has a genomic organization similar to HD-5, and the two genes have a striking pattern of sequence similarity localized chiefly in their proximal 5'-flanking regions. Analysis of human fetal RNA by reverse transcriptase-PCR detected enteric defensin HD-5 mRNA at 13.5 weeks of gestation in the small intestine and the colon, but by 17 weeks HD-5 was restricted to the small intestine. HD-6 mRNA was detectable at 13.5-17 weeks of gestation in the small intestine but not in the colon. This pattern of expression coincides with the previously described appearance of Paneth cells as determined by ultrastructural approaches. Northern analysis of total RNA from small intestine revealed quantifiable enteric defensin mRNA in five samples from 19 24 weeks of gestation at levels approximately 40-250-fold less than those observed in the adult, with HD-5 mRNA levels greater than those of HD-6 in all samples. In situ hybridization analysis localized expression of enteric defensin mRNA to Paneth cells at 24 weeks of gestation, as is seen in the newborn term infant and the adult. Consistent with earlier morphological studies, the ratio of Paneth cell number per crypt was reduced in samples at 24 weeks of gestation compared with the adult, and this lower cell number partially accounts for the lower defensin mRNA levels as determined by Northern analysis. Low levels of enteric defensin expression in the fetus may be characteristic of an immaturity of local defense, which is thought to predispose infants born prematurely to infection from intestinal microorganisms.
- Published
- 1996
24. 669 In vivocharacterization of melanoma metabolism in human patients through intraoperative [U-13C] glucose infusions
- Author
-
Gill, J.G., Rao, A., Player, D., Sharma, R., Tillman, B., Huth, J., Homsi, J., Vandergriff, T., and Deberardinis, R.
- Published
- 2021
- Full Text
- View/download PDF
25. Metabolic rewiring in fat-depleted Drosophila reveals triglyceride:glycogen crosstalk and identifies cDIP as a new regulator of energy metabolism.
- Author
-
Henne WM, Ugrankar-Banerjee R, Tran S, Bowerman J, Paul B, Zacharias L, Mathews T, and DeBerardinis R
- Abstract
Tissues store excess nutrients as triglyceride or glycogen, but how these reserves are sensed and communicate remains poorly understood. Here we identify molecular players orchestrating this metabolic balance during fat depletion. We show fat body (FB)-specific depletion of fatty acyl-CoA synthase FASN1 in Drosophila causes near-complete fat loss and metabolic remodeling that dramatically elevates glycogen storage and carbohydrate metabolism. Proteomics and metabolomics identify key factors necessary for rewiring including glycolysis enzymes and target-of-brain-insulin (tobi). FASN1-deficient flies are viable but starvation sensitive, oxidatively stressed, and infertile. We also identify CG10824/cDIP as upregulated in FASN1-depleted Drosophila. cDIP is a leucine-rich-repeat protein with homology to secreted adipokines that fine-tune energy signaling, and is required for fly development in the absence of FASN1. Collectively, we show fat-depleted Drosophila rewire their metabolism to complete development, and identify cDIP as a putative new cytokine that signals fat insufficiency and may regulate energy homeostasis.
- Published
- 2024
- Full Text
- View/download PDF
26. An interactive web application for exploring human plasma and fibroblast metabolomics data from patients with inborn errors of metabolism.
- Author
-
Cai L, Vu HS, Gu W, Chen H, Franklin J, Haidar LA, Wu Z, Pan C, Cai F, Nguyen P, Ko B, Yang C, Zacharias LG, Sudderth J, Montgomery S, Uhles C, Fisher H, Hudnall J, Hornbuckle C, Quinn C, Michel D, Umaña L, Scheuerle A, McNutt MC, Gotway GK, Afroze B, Ni M, and DeBerardinis R
- Abstract
Metabolomic profiling is instrumental in understanding the systemic and cellular impact of inborn errors of metabolism (IEMs), monogenic disorders caused by pathogenic genomic variants in genes involved in metabolism. This study encompasses untargeted metabolomics analysis of plasma from 474 individuals and fibroblasts from 67 subjects, incorporating healthy controls, patients with 65 different monogenic diseases, and numerous undiagnosed cases. We introduce a web application designed for the in-depth exploration of this extensive metabolomics database. The application offers a user-friendly interface for data review, download, and detailed analysis of metabolic deviations linked to IEMs at the level of individual patients or groups of patients with the same diagnosis. It also provides interactive tools for investigating metabolic relationships and offers comparative analyses of plasma and fibroblast profiles. This tool emphasizes the metabolic interplay within and across biological matrices, enriching our understanding of metabolic regulation in health and disease. As a resource, the application provides broad utility in research, offering novel insights into metabolic pathways and their alterations in various disorders.
- Published
- 2023
- Full Text
- View/download PDF
27. FASN deficiency induces a cytosol-to-mitochondria citrate flux to mitigate detachment-induced oxidative stress.
- Author
-
Dai W, Wang Z, Wang G, Wang QA, DeBerardinis R, and Jiang L
- Subjects
- Cytosol metabolism, Cell Line, Tumor, Citrates metabolism, Oxidative Stress, Nitric Oxide Synthase metabolism, Fatty Acid Synthases metabolism, Mitochondria metabolism, Lipogenesis, Citric Acid metabolism, Isocitrate Dehydrogenase genetics, Isocitrate Dehydrogenase metabolism
- Abstract
Fatty acid synthase (FASN) maintains de novo lipogenesis (DNL) to support rapid growth in most proliferating cancer cells. Lipogenic acetyl-coenzyme A (CoA) is primarily produced from carbohydrates but can arise from glutamine-dependent reductive carboxylation. Here, we show that reductive carboxylation also occurs in the absence of DNL. In FASN-deficient cells, reductive carboxylation is mainly catalyzed by isocitrate dehydrogenase-1 (IDH1), but IDH1-generated cytosolic citrate is not utilized for supplying DNL. Metabolic flux analysis (MFA) shows that FASN deficiency induces a net cytosol-to-mitochondria citrate flux through mitochondrial citrate transport protein (CTP). Previously, a similar pathway has been shown to mitigate detachment-induced oxidative stress in anchorage-independent tumor spheroids. We further report that tumor spheroids show reduced FASN activity and that FASN-deficient cells acquire resistance to oxidative stress in a CTP- and IDH1-dependent manner. Collectively, these data indicate that by inducing a cytosol-to-mitochondria citrate flux, anchorage-independent malignant cells can gain redox capacity by trading off FASN-supported rapid growth., Competing Interests: Declaration of interests R.D. is a founder and advisor at Atavistik Bio and serves on the scientific advisory boards of Agios Pharmaceuticals and Vida Ventures., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. Optimized protocol for stable isotope tracing and steady-state metabolomics in mouse HER2+ breast cancer brain metastasis.
- Author
-
Parida PK, Marquez-Palencia M, Kaushik AK, Kim K, Nair V, Sudderth J, Vu H, Zacharias L, DeBerardinis R, and Malladi S
- Subjects
- Animals, Isotope Labeling methods, Isotopes, Mass Spectrometry, Mice, Brain Neoplasms diagnosis, Metabolomics methods
- Abstract
Analyzing the metabolic dependencies of tumor cells is vital for cancer diagnosis and treatment. Here, we describe a protocol for
13 C-stable glucose and glutamine isotope tracing in mice HER2+ breast cancer brain metastatic lesions. We describe how to inject cancer cells intracardially to generate brain metastatic lesions in mice. We then detail how to perform13 C-stable isotope infusion in mice with established brain metastasis. Finally, we outline steps for sample collection, processing for metabolite extraction, and analyzing mass spectrometry data. For complete details on the use and execution of this protocol, please refer to Parida et al. (2022)., Competing Interests: R.J.D. is a founder of Atavistik Biosciences and an advisor for Agios Pharmaceuticals, Nirogy Therapeutics, and Vida Ventures., (© 2022 The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
29. Leveraging insights into cancer metabolism-a symposium report.
- Author
-
Cable J, Finley L, Tu BP, Patti GJ, Oliver TG, Vardhana S, Mana M, Ericksen R, Khare S, DeBerardinis R, Stockwell BR, Edinger A, Haigis M, and Kaelin W
- Subjects
- Animals, Cell Transformation, Neoplastic metabolism, Humans, Metabolic Networks and Pathways physiology, New York City, Congresses as Topic trends, Energy Metabolism physiology, Neoplasms metabolism, Research Report trends
- Abstract
Tumor cells have devised unique metabolic strategies to garner enough nutrients to sustain continuous growth and cell division. Oncogenic mutations may alter metabolic pathways to unlock new sources of energy, and cells take the advantage of various scavenging pathways to ingest material from their environment. These changes in metabolism result in a metabolic profile that, in addition to providing the building blocks for macromolecules, can also influence cell signaling pathways to promote tumor initiation and progression. Understanding what pathways tumor cells use to synthesize the materials necessary to support metabolic growth can pave the way for new cancer therapeutics. Potential strategies include depriving tumors of the materials needed to grow or targeting pathways involved in dependencies that arise by virtue of their altered metabolis., (© 2019 New York Academy of Sciences.)
- Published
- 2020
- Full Text
- View/download PDF
30. γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.
- Author
-
Gao X, Zhao L, Liu S, Li Y, Xia S, Chen D, Wang M, Wu S, Dai Q, Vu H, Zacharias L, DeBerardinis R, Lim E, Metallo C, Boggon TJ, Lonial S, Lin R, Mao H, Pan Y, Shan C, and Chen J
- Subjects
- A549 Cells, AMP-Activated Protein Kinase Kinases, Animals, Cell Proliferation, Enzyme Activation, Glucosephosphate Dehydrogenase genetics, Glucosephosphate Dehydrogenase metabolism, HEK293 Cells, HT29 Cells, Humans, K562 Cells, MCF-7 Cells, Mice, Nude, Neoplasms genetics, Neoplasms pathology, PC-3 Cells, Pentose Phosphate Pathway, Protein Binding, Protein Phosphatase 2 genetics, Protein Serine-Threonine Kinases metabolism, Reactive Oxygen Species metabolism, Ribulosephosphates metabolism, Signal Transduction, Superoxide Dismutase genetics, Superoxide Dismutase metabolism, Tumor Burden, src-Family Kinases metabolism, AMP-Activated Protein Kinases metabolism, Gluconates metabolism, Neoplasms enzymology, Protein Phosphatase 2 metabolism
- Abstract
The oxidative pentose phosphate pathway (oxiPPP) contributes to cell metabolism through not only the production of metabolic intermediates and reductive NADPH but also inhibition of LKB1-AMPK signaling by ribulose-5-phosphate (Ru-5-P), the product of the third oxiPPP enzyme 6-phosphogluconate dehydrogenase (6PGD). However, we found that knockdown of glucose-6-phosphate dehydrogenase (G6PD), the first oxiPPP enzyme, did not affect AMPK activation despite decreased Ru-5-P and subsequent LKB1 activation, due to enhanced activity of PP2A, the upstream phosphatase of AMPK. In contrast, knockdown of 6PGD or 6-phosphogluconolactonase (PGLS), the second oxiPPP enzyme, reduced PP2A activity. Mechanistically, knockdown of G6PD or PGLS decreased or increased 6-phosphogluconolactone level, respectively, which enhanced the inhibitory phosphorylation of PP2A by Src. Furthermore, γ-6-phosphogluconolactone, an oxiPPP byproduct with unknown function generated through intramolecular rearrangement of δ-6-phosphogluconolactone, the only substrate of PGLS, bound to Src and enhanced PP2A recruitment. Together, oxiPPP regulates AMPK homeostasis by balancing the opposing LKB1 and PP2A., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
31. Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid.
- Author
-
Menon D, Salloum D, Bernfeld E, Gorodetsky E, Akselrod A, Frias MA, Sudderth J, Chen PH, DeBerardinis R, and Foster DA
- Subjects
- Female, G1 Phase Cell Cycle Checkpoints drug effects, Hep G2 Cells, Humans, MCF-7 Cells, Male, Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Multiprotein Complexes genetics, Oleic Acid pharmacology, Phosphatidic Acids genetics, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, TOR Serine-Threonine Kinases genetics, Multiprotein Complexes metabolism, Phosphatidic Acids biosynthesis, TOR Serine-Threonine Kinases metabolism
- Abstract
mTOR, the mammalian target of rapamycin, integrates growth factor and nutrient signals to promote a transformation from catabolic to anabolic metabolism, cell growth, and cell cycle progression. Phosphatidic acid (PA) interacts with the FK506-binding protein-12-rapamycin-binding (FRB) domain of mTOR, which stabilizes both mTOR complexes: mTORC1 and mTORC2. We report here that mTORC1 and mTORC2 are activated in response to exogenously supplied fatty acids via the de novo synthesis of PA, a central metabolite for membrane phospholipid biosynthesis. We examined the impact of exogenously supplied fatty acids on mTOR in KRas-driven cancer cells, which are programmed to utilize exogenous lipids. The induction of mTOR by oleic acid was dependent upon the enzymes responsible for de novo synthesis of PA. Suppression of the de novo synthesis of PA resulted in G
1 cell cycle arrest. Although it has long been appreciated that mTOR is a sensor of amino acids and glucose, this study reveals that mTOR also senses the presence of lipids via production of PA., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)- Published
- 2017
- Full Text
- View/download PDF
32. Evidence of Glycolysis Up-Regulation and Pyruvate Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning.
- Author
-
Diakos NA, Navankasattusas S, Abel ED, Rutter J, McCreath L, Ferrin P, McKellar SH, Miller DV, Park SY, Richardson RS, Deberardinis R, Cox JE, Kfoury AG, Selzman CH, Stehlik J, Fang JC, Li DY, and Drakos SG
- Abstract
This study sought to investigate the effects of mechanical unloading on myocardial energetics and the metabolic perturbation of heart failure (HF) in an effort to identify potential new therapeutic targets that could enhance the unloading-induced cardiac recovery. The authors prospectively examined paired human myocardial tissue procured from 31 advanced HF patients at left ventricular assist device (LVAD) implant and at heart transplant plus tissue from 11 normal donors. They identified increased post-LVAD glycolytic metabolites without a coordinate increase in early, tricarboxylic acid (TCA) cycle intermediates. The increased pyruvate was not directed toward the mitochondria and the TCA cycle for complete oxidation, but instead, was mainly converted to cytosolic lactate. Increased nucleotide concentrations were present, potentially indicating increased flux through the pentose phosphate pathway. Evaluation of mitochondrial function and structure revealed a lack of post-LVAD improvement in mitochondrial oxidative functional capacity, mitochondrial volume density, and deoxyribonucleic acid content. Finally, post-LVAD unloading, amino acid levels were found to be increased and could represent a compensatory mechanism and an alternative energy source that could fuel the TCA cycle by anaplerosis. In summary, the authors report evidence that LVAD unloading induces glycolysis in concert with pyruvate mitochondrial oxidation mismatch, most likely as a result of persistent mitochondrial dysfunction. These findings suggest that interventions known to improve mitochondrial biogenesis, structure, and function, such as controlled cardiac reloading and conditioning, warrant further investigation to enhance unloading-induced reverse remodeling and cardiac recovery.
- Published
- 2016
- Full Text
- View/download PDF
33. Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring.
- Author
-
Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, deBerardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, Viteri B, Egigueron M, Shah N, and Hoberman A
- Subjects
- Child, Preschool, Cicatrix etiology, Cicatrix pathology, Female, Follow-Up Studies, Humans, Incidence, Infant, Male, Prospective Studies, Recurrence, Risk Factors, United States epidemiology, Urinary Tract Infections complications, Urinary Tract Infections drug therapy, Vesico-Ureteral Reflux diagnosis, Anti-Bacterial Agents therapeutic use, Antibiotic Prophylaxis methods, Cicatrix epidemiology, Kidney pathology, Risk Assessment methods, Urinary Tract Infections epidemiology, Vesico-Ureteral Reflux complications
- Abstract
Objectives: To identify risk factors for recurrent urinary tract infection (UTI) and renal scarring in children who have had 1 or 2 febrile or symptomatic UTIs and received no antimicrobial prophylaxis., Methods: This 2-year, multisite prospective cohort study included 305 children aged 2 to 71 months with vesicoureteral reflux (VUR) receiving placebo in the RIVUR (Randomized Intervention for Vesicoureteral Reflux) study and 195 children with no VUR observed in the CUTIE (Careful Urinary Tract Infection Evaluation) study. Primary exposure was presence of VUR; secondary exposures included bladder and bowel dysfunction (BBD), age, and race. Outcomes were recurrent febrile or symptomatic urinary tract infection (F/SUTI) and renal scarring., Results: Children with VUR had higher 2-year rates of recurrent F/SUTI (Kaplan-Meier estimate 25.4% compared with 17.3% for VUR and no VUR, respectively). Other factors associated with recurrent F/SUTI included presence of BBD at baseline (adjusted hazard ratio: 2.07 [95% confidence interval (CI): 1.09-3.93]) and presence of renal scarring on the baseline (99m)Tc-labeled dimercaptosuccinic acid scan (adjusted hazard ratio: 2.88 [95% CI: 1.22-6.80]). Children with BBD and any degree of VUR had the highest risk of recurrent F/SUTI (56%). At the end of the 2-year follow-up period, 8 (5.6%) children in the no VUR group and 24 (10.2%) in the VUR group had renal scars, but the difference was not statistically significant (adjusted odds ratio: 2.05 [95% CI: 0.86-4.87])., Conclusions: VUR and BBD are risk factors for recurrent UTI, especially when they appear in combination. Strategies for preventing recurrent UTI include antimicrobial prophylaxis and treatment of BBD., (Copyright © 2015 by the American Academy of Pediatrics.)
- Published
- 2015
- Full Text
- View/download PDF
34. Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children.
- Author
-
Keren R, Shah SS, Srivastava R, Rangel S, Bendel-Stenzel M, Harik N, Hartley J, Lopez M, Seguias L, Tieder J, Bryan M, Gong W, Hall M, Localio R, Luan X, deBerardinis R, and Parker A
- Subjects
- Acute Disease, Administration, Oral, Adolescent, Anti-Bacterial Agents adverse effects, Child, Child, Preschool, Cohort Studies, Emergency Service, Hospital statistics & numerical data, Female, Humans, Infusions, Intravenous methods, Male, Patient Discharge, Patient Readmission statistics & numerical data, Propensity Score, Retrospective Studies, Anti-Bacterial Agents administration & dosage, Catheterization, Peripheral adverse effects, Osteomyelitis drug therapy
- Abstract
Importance: Postdischarge treatment of acute osteomyelitis in children requires weeks of antibiotic therapy, which can be administered orally or intravenously via a peripherally inserted central catheter (PICC). The catheters carry a risk for serious complications, but limited evidence exists on the effectiveness of oral therapy., Objective: To compare the effectiveness and adverse outcomes of postdischarge antibiotic therapy administered via the PICC or the oral route., Design, Setting, and Participants: We performed a retrospective cohort study comparing PICC and oral therapy for the treatment of acute osteomyelitis. Among children hospitalized from January 1, 2009, through December 31, 2012, at 36 participating children's hospitals, we used discharge codes to identify potentially eligible participants. Results of medical record review confirmed eligibility and defined treatment group allocation and study outcomes. We used within- and across-hospital propensity score-based full matching to adjust for confounding by indication., Interventions: Postdischarge administration of antibiotics via the PICC or the oral route., Main Outcomes and Measures: The primary outcome was treatment failure. Secondary outcomes included adverse drug reaction, PICC line complication, and a composite of all 3 end points., Results: Among 2060 children and adolescents (hereinafter referred to as children) with osteomyelitis, 1005 received oral antibiotics at discharge, whereas 1055 received PICC-administered antibiotics. The proportion of children treated via the PICC route varied across hospitals from 0 to 100%. In the across-hospital (risk difference, 0.3% [95% CI, -0.1% to 2.5%]) and within-hospital (risk difference, 0.6% [95% CI, -0.2% to 3.0%]) matched analyses, children treated with antibiotics via the oral route (reference group) did not experience more treatment failures than those treated with antibiotics via the PICC route. Rates of adverse drug reaction were low (<4% in both groups) but slightly greater in the PICC group in across-hospital (risk difference, 1.7% [95% CI, 0.1%-3.3%]) and within-hospital (risk difference, 2.1% [95% CI, 0.3%-3.8%]) matched analyses. Among the children in the PICC group, 158 (15.0%) had a PICC complication that required an emergency department visit (n = 96), a rehospitalization (n = 38), or both (n = 24). As a result, the PICC group had a much higher risk of requiring a return visit to the emergency department or for hospitalization for any adverse outcome in across-hospital (risk difference, 14.6% [95% CI, 11.3%-17.9%]) and within-hospital (risk difference, 14.0% [95% CI, 10.5%-17.6%]) matched analyses., Conclusions and Relevance: Given the magnitude and seriousness of PICC complications, clinicians should reconsider the practice of treating otherwise healthy children with acute osteomyelitis with prolonged intravenous antibiotics after hospital discharge when an equally effective oral alternative exists.
- Published
- 2015
- Full Text
- View/download PDF
35. The cancer cell 'energy grid': TGF-β1 signaling coordinates metabolism for migration.
- Author
-
Jiang L, Deberardinis R, and Boothman DA
- Abstract
Cancer cells have an increased reliance on lipogenesis, which is required for uncontrolled cell division. We recently reported transcriptional and functional 'reprogramming' of the cellular energy grid, allowing cancer cells to divert metabolism from biosynthesis to bioenergetic pathways and thus supplying enhanced mobility during epithelial-mesenchymal transition (EMT) induced by transforming growth factor β (TGF-β1) (Fig. 1).
- Published
- 2015
- Full Text
- View/download PDF
36. The gut commensal Bacteroides thetaiotaomicron exacerbates enteric infection through modification of the metabolic landscape.
- Author
-
Curtis MM, Hu Z, Klimko C, Narayanan S, Deberardinis R, and Sperandio V
- Subjects
- Animals, Bacteroides genetics, Citrobacter rodentium genetics, Citrobacter rodentium physiology, Enterohemorrhagic Escherichia coli genetics, Enterohemorrhagic Escherichia coli physiology, Female, Gluconeogenesis, Humans, Mice, Mice, Inbred C3H, Microbiota, Succinic Acid metabolism, Symbiosis, Bacteroides physiology, Enterobacteriaceae Infections metabolism, Enterobacteriaceae Infections microbiology, Gastrointestinal Tract metabolism, Gastrointestinal Tract microbiology
- Abstract
The enteric pathogen enterohemorrhagic Escherichia coli (EHEC) causes severe diarrhea, but the influence of the gut microbiota on EHEC infection is largely unknown. A predominant member of the microbiota, Bacteroides thetaiotaomicron (Bt), is resident at EHEC attachment sites. We show that Bt enhances EHEC virulence gene expression through the transcription factor Cra, which is functionally sensitive to sugar concentrations. This enhanced virulence accompanies increased formation of attaching and effacing (AE) lesions requisite for EHEC colonization. Infection with Citrobacter rodentium, a natural mouse pathogen homologous to EHEC, in Bt-reconstituted mice results in increased gut permeability along with exacerbated host pathology and mortality compared to mice deplete of microflora. Bt modifies the metabolite environment at infection sites, increasing metabolites involved in gluconeogenesis, with stark increases in succinate, which can be sensed by Cra. Our findings suggest that microbiota composition affects disease outcome and may explain links between microbiota composition and disease susceptibility., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
37. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
- Author
-
Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, Zhang S, Pichumani K, Mendelsohn D, Mickey B, Malloy C, Bachoo R, Deberardinis R, and Maher E
- Subjects
- Adult, Aspartic Acid analogs & derivatives, Aspartic Acid metabolism, Brain Neoplasms enzymology, Brain Neoplasms genetics, Glioma enzymology, Glioma genetics, Glutamic Acid metabolism, Glutamine metabolism, Humans, Isocitrate Dehydrogenase genetics, Middle Aged, Mutation genetics, Phantoms, Imaging, Young Adult, gamma-Aminobutyric Acid metabolism, Brain Neoplasms metabolism, Glioma metabolism, Glutarates metabolism, Magnetic Resonance Spectroscopy methods, Protons
- Abstract
2-Hydroxyglutarate (2HG) is produced in gliomas with mutations of isocitrate dehydrogenase (IDH) 1 and 2. The (1) H resonances of the J-coupled spins of 2HG are extensively overlapped with signals from other metabolites. Here, we report a comparative study at 3 T of the utility of the point-resolved spectroscopy sequence with a standard short TE (35 ms) and a long TE (97 ms), which had been theoretically designed for the detection of the 2HG 2.25-ppm resonance. The performance of the methods is evaluated using data from phantoms, seven healthy volunteers and 22 subjects with IDH-mutated gliomas. The results indicate that TE = 97 ms provides higher detectability of 2HG than TE = 35 ms, and that this improved capability is gained when data are analyzed with basis spectra that include the effects of the volume localizing radiofrequency and gradient pulses., (Copyright © 2013 John Wiley & Sons, Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
38. What can ADHD without comorbidity teach us about comorbidity?
- Author
-
Takeda T, Ambrosini PJ, deBerardinis R, and Elia J
- Subjects
- Adolescent, Adult, Age Distribution, Attention Deficit Disorder with Hyperactivity psychology, Child, Comorbidity, Fathers psychology, Female, Humans, Male, Mothers psychology, Prevalence, Risk Factors, Attention Deficit Disorder with Hyperactivity epidemiology, Family Health statistics & numerical data, Fathers statistics & numerical data, Mental Disorders epidemiology, Mothers statistics & numerical data
- Abstract
Neuropsychiatric comorbidity in ADHD is frequent, impairing and poorly understood. In this report, characteristics of comorbid and comorbid-free ADHD subjects are investigated in an attempt to identify differences that could potentially advance our understanding of risk factors. In a clinically-referred ADHD cohort of 449 youths (ages 6-18), age, gender, IQ, SES and ADHD symptoms were compared among ADHD comorbid free subjects and ADHD with internalizing and externalizing disorders. Logistic regression analyses were also carried out to investigate the relationship between comorbidity and parental psychiatric status. Age range was younger in the ADHD without comorbidity and older in ADHD+internalizing disorders. No significant difference in IQ or SES was found among ADHD comorbid and comorbid-free groups. ADHD with internalizing disorder has a significantly greater association with paternal psychiatric conditions. After matching by age, gender, IQ and SES, ADHD with externalizing disorders had significantly higher total ADHD, hyperactivity/impulsivity score and single item score of difficulty awaiting turn than ADHD without comorbidity and ADHD with internalizing disorders. Older age ranges, ADHD symptom severity and parental psychopathology may be risk factors for comorbidity., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
39. Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis.
- Author
-
Gribouval O, Morinière V, Pawtowski A, Arrondel C, Sallinen SL, Saloranta C, Clericuzio C, Viot G, Tantau J, Blesson S, Cloarec S, Machet MC, Chitayat D, Thauvin C, Laurent N, Sampson JR, Bernstein JA, Clemenson A, Prieur F, Daniel L, Levy-Mozziconacci A, Lachlan K, Alessandri JL, Cartault F, Rivière JP, Picard N, Baumann C, Delezoide AL, Belar Ortega M, Chassaing N, Labrune P, Yu S, Firth H, Wellesley D, Bitzan M, Alfares A, Braverman N, Krogh L, Tolmie J, Gaspar H, Doray B, Majore S, Bonneau D, Triau S, Loirat C, David A, Bartholdi D, Peleg A, Brackman D, Stone R, DeBerardinis R, Corvol P, Michaud A, Antignac C, and Gubler MC
- Subjects
- Angiotensinogen genetics, Animals, Disease Models, Animal, Genetic Association Studies, Humans, Kidney Tubules, Proximal abnormalities, Peptidyl-Dipeptidase A genetics, Receptor, Angiotensin, Type 1 genetics, Renin genetics, Urogenital Abnormalities diagnosis, Genes, Recessive, Mutation, Renin-Angiotensin System genetics, Urogenital Abnormalities genetics
- Abstract
Autosomal recessive renal tubular dysgenesis (RTD) is a severe disorder of renal tubular development characterized by early onset and persistent fetal anuria leading to oligohydramnios and the Potter sequence, associated with skull ossification defects. Early death occurs in most cases from anuria, pulmonary hypoplasia, and refractory arterial hypotension. The disease is linked to mutations in the genes encoding several components of the renin-angiotensin system (RAS): AGT (angiotensinogen), REN (renin), ACE (angiotensin-converting enzyme), and AGTR1 (angiotensin II receptor type 1). Here, we review the series of 54 distinct mutations identified in 48 unrelated families. Most of them are novel and ACE mutations are the most frequent, observed in two-thirds of families (64.6%). The severity of the clinical course was similar whatever the mutated gene, which underlines the importance of a functional RAS in the maintenance of blood pressure and renal blood flow during the life of a human fetus. Renal hypoperfusion, whether genetic or secondary to a variety of diseases, precludes the normal development/ differentiation of proximal tubules. The identification of the disease on the basis of precise clinical and histological analyses and the characterization of the genetic defects allow genetic counseling and early prenatal diagnosis., (© 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
40. Nocturnal enuresis: a suggestive endophenotype marker for a subgroup of inattentive attention-deficit/hyperactivity disorder.
- Author
-
Elia J, Takeda T, Deberardinis R, Burke J, Accardo J, Ambrosini PJ, Blum NJ, Brown LW, Lantieri F, Berrettini W, Devoto M, and Hakonarson H
- Subjects
- Arousal, Case-Control Studies, Child, Chromosomes, Human genetics, Female, Genetic Markers, Humans, Male, Phenotype, Polymorphism, Single Nucleotide, Severity of Illness Index, Sleep Initiation and Maintenance Disorders epidemiology, Attention Deficit Disorder with Hyperactivity epidemiology, Attention Deficit Disorder with Hyperactivity genetics, Nocturnal Enuresis epidemiology, Nocturnal Enuresis genetics
- Abstract
Objective: Attention-deficit/hyperactivity disorder (ADHD) and enuresis co-occur at a higher rate than expected; the cause for this is unclear., Study Design: Diagnostic and demographic variables were compared in 344 children ages 6 to 12 years, with and without enuresis, recruited in an ADHD genetic study. Sleep variables were investigated in a subgroup of 44 enuretic children with age- and sex-matched nonenuretic controls. The association of enuresis with single nucleotide polymorphisms located in regions reported in linkage with enuresis was explored., Results: The prevalence rate of nocturnal enuresis was 16.9% for the entire cohort. There were no differences in sex, age, socioeconomic status, intelligence quotient, medication treatment, or comorbidities. The enuresis group had a higher likelihood of inattentive symptoms than the nonenuretic group. Night wakings and ability of children to wake themselves in the morning were both significantly decreased in children with enuresis compared with control children in the Child Sleep Habits Questionnaire Night Wakings subscale. No significant association was found with chromosomal regions previously reported in linkage with enuresis., Conclusions: Deficits in arousal may contribute to both enuresis and inattentive ADHD. Nocturnal enuresis may be a useful clinical marker in identifying a subgroup of the inattentive phenotype in ADHD genetic studies.
- Published
- 2009
- Full Text
- View/download PDF
41. Analysis of the promoter from an expanding mouse retrotransposon subfamily.
- Author
-
DeBerardinis RJ and Kazazian HH Jr
- Subjects
- Animals, Base Sequence, CpG Islands genetics, Mice, Models, Genetic, Molecular Sequence Data, Polymorphism, Genetic, Sequence Analysis, DNA, Transcription, Genetic, beta-Galactosidase analysis, Promoter Regions, Genetic genetics, Retroelements genetics
- Abstract
The mouse genome contains several subfamilies of the retrotransposon L1. One subfamily, TF, contains 4000-5000 full-length members and is expanding due to retrotransposition of a large number of active elements. Here we studied the TF 5' untranslated region (UTR), which contains promoter activity required for subfamily expression. Using reporter assays, we show that promoter activity is derived from TF-specific monomer sequences and is proportional to the number of monomers in the 5' UTR. These data suggest that nearly all full-length TF elements in the mouse genome are currently competent for expression. We aligned the sequences of 53 monomers to generate a consensus TF monomer and determined that most TF elements are truncated near a potential binding site for a transcription initiation factor. We also determined that much of the sequence variation among TF monomers results from transition mutations at CpG dinucleotides, suggesting that genomic TF 5' UTRs are methylated at CpGs., (Copyright 1999 Academic Press.)
- Published
- 1999
- Full Text
- View/download PDF
42. Exon shuffling by L1 retrotransposition.
- Author
-
Moran JV, DeBerardinis RJ, and Kazazian HH Jr
- Subjects
- Codon, Initiator, Expressed Sequence Tags, Gene Expression, Gentamicins pharmacology, HeLa Cells, Humans, Introns, Poly A metabolism, Promoter Regions, Genetic, Transcription, Genetic, Exons genetics, Genome, Human, Long Interspersed Nucleotide Elements genetics, Recombination, Genetic
- Abstract
Long interspersed nuclear elements (LINE-1s or L1s) are the most abundant retrotransposons in the human genome, and they serve as major sources of reverse transcriptase activity. Engineered L1s retrotranspose at high frequency in cultured human cells. Here it is shown that L1s insert into transcribed genes and retrotranspose sequences derived from their 3' flanks to new genomic locations. Thus, retrotransposition-competent L1s provide a vehicle to mobilize non-L1 sequences, such as exons or promoters, into existing genes and may represent a general mechanism for the evolution of new genes.
- Published
- 1999
- Full Text
- View/download PDF
43. Rapid amplification of a retrotransposon subfamily is evolving the mouse genome.
- Author
-
DeBerardinis RJ, Goodier JL, Ostertag EM, and Kazazian HH Jr
- Subjects
- 5' Untranslated Regions, Animals, Humans, Mice, Molecular Sequence Data, Mutation, Polymorphism, Genetic, Retroelements, Species Specificity, Evolution, Molecular, Gene Amplification, Genome
- Abstract
Retrotransposition affects genome structure by increasing repetition and producing insertional mutations. Dispersion of the retrotransposon L1 throughout mammalian genomes suggests that L1 activity might be an important evolutionary force. Here we report that L1 retrotransposition contributes to rapid genome evolution in the mouse, because a number of L1 sequences from the T(F) subfamily are retrotransposition competent. We show that the T(F) subfamily is large, young and expanding, containing approximately 4,800 full-length members in strain 129. Eleven randomly isolated, full-length T(F) elements averaged 99.8% sequence identity to each other, and seven of these retrotransposed in cultured cells. Thus, we estimate that the mouse genome contains approximately 3,000 active T(F) elements, 75 times the estimated number of active human L1s. Moreover, as T(F) elements are polymorphic among closely related mice, they have retrotransposed recently, implying rapid amplification of the subfamily to yield genomes with different patterns of interspersed repetition. Our data show that mice and humans differ considerably in the number of active L1s, and probably differ in the contribution of retrotransposition to ongoing sequence evolution.
- Published
- 1998
- Full Text
- View/download PDF
44. Full-length L1 elements have arisen recently in the same 1-kb region of the gorilla and human genomes.
- Author
-
DeBerardinis RJ and Kazazian HH Jr
- Subjects
- Alleles, Animals, Base Sequence, Chromosome Mapping, Gene Frequency, Humans, Molecular Sequence Data, Open Reading Frames genetics, Phylogeny, Sequence Analysis, DNA, Evolution, Molecular, Genome, Human, Gorilla gorilla genetics, Retroelements genetics
- Abstract
New copies of the mammalian retrotransposon L1 arise in the germline at an undetermined rate. Each new L1 copy appears at a specific evolutionary time point that can be estimated by phylogenetic analysis. In humans, the active L1 sequence L1.2 resides at the genomic locus LRE1. Here we analyzed the region surrounding the LRE1 locus in humans and gorillas to determine the evolutionary history of the region and to estimate the age of L1.2. We found that the region was composed of an ancient L1, L1Hs-Lrg, which was significantly divergent from all other L1 sequences available in the databases. We also determined that L1.2 was absent from the gorilla genome and arose in humans after the divergence of gorilla and human lineages. In the gorilla LRE1 region, we discovered a different full-length L1 element, L1Gg-1, which was allelic and present at a high gene frequency in gorillas but absent from other primates. We determined the nucleotide sequence of L1Gg-1 and found that it was 98% identical to L1.2, suggesting a close relationship between active L1s in gorillas and humans.
- Published
- 1998
- Full Text
- View/download PDF
45. An actively retrotransposing, novel subfamily of mouse L1 elements.
- Author
-
Naas TP, DeBerardinis RJ, Moran JV, Ostertag EM, Kingsmore SF, Seldin MF, Hayashizaki Y, Martin SL, and Kazazian HH
- Subjects
- Animals, Base Sequence, HeLa Cells, Humans, Mice, Mice, Inbred Strains, Molecular Sequence Data, Promoter Regions, Genetic, RNA analysis, RNA-Directed DNA Polymerase genetics, Ribonucleoproteins genetics, Multigene Family, Retroelements
- Abstract
Retrotransposition of LINEs and other retroelements increases repetition in mammalian genomes and can cause deleterious mutations. Recent insertions of two full-length L1s, L1spa and L1Orl, caused the disease phenotypes of the spastic and Orleans reeler mice respectively. Here we show that these two recently retrotransposed L1s are nearly identical in sequence, have two open reading frames and belong to a novel subfamily related to the ancient F subfamily. We have named this new subfamily TF (for transposable) and show that many full-length members of this family are present in the mouse genome. The TF 5' untranslated region has promoter activity, and TF-type RNA is abundant in cytoplasmic ribonucleoprotein particles, which are likely intermediates in retrotransposition. Both L1spa and L1Orl have reverse transcriptase activity in a yeast-based assay and retrotranspose at high frequency in cultured cells. Together, our data indicate that the TF subfamily of L1s contains a major class of mobile elements that is expanding in the mouse genome.
- Published
- 1998
- Full Text
- View/download PDF
46. Many human L1 elements are capable of retrotransposition.
- Author
-
Sassaman DM, Dombroski BA, Moran JV, Kimberland ML, Naas TP, DeBerardinis RJ, Gabriel A, Swergold GD, and Kazazian HH Jr
- Subjects
- Animals, Chromosome Mapping, Gene Frequency, Genome, Human, HeLa Cells, Humans, Mice, Molecular Sequence Data, RNA-Directed DNA Polymerase genetics, RNA-Directed DNA Polymerase metabolism, Sequence Analysis, DNA, Chromosomes, Human, Repetitive Sequences, Nucleic Acid, Retroelements genetics
- Abstract
Using a selective screening strategy to enrich for active L1 elements, we isolated 13 full-length elements from a human genomic library. We tested these and two previously-isolated L1s (L1.3 and L1.4) for reverse transcriptase (RT) activity and the ability to retrotranspose in HeLa cells. Of the 13 newly-isolated L1s, eight had RT activity and three were able to retrotranspose. L1.3 and L1.4 possessed RT activity and retrotransposed at remarkably high frequencies. These studies bring the number of characterized active human L1 elements to seven. Based on these and other data, we estimate that 30-60 active L1 elements reside in the average diploid genome.
- Published
- 1997
- Full Text
- View/download PDF
47. High frequency retrotransposition in cultured mammalian cells.
- Author
-
Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, and Kazazian HH Jr
- Subjects
- Animals, Base Sequence, Chromosomes genetics, Conserved Sequence, Cysteine genetics, DNA Mutational Analysis, Fibroblasts physiology, Genome, HeLa Cells physiology, Humans, Mammals, Mice, Mutagenesis genetics, Open Reading Frames genetics, Promoter Regions, Genetic genetics, RNA, Messenger genetics, Time Factors, Retroelements genetics
- Abstract
We previously isolated two human L1 elements (L1.2 and LRE2) as the progenitors of disease-producing insertions. Here, we show these elements can actively retrotranspose in cultured mammalian cells. When stably expressed from an episome in HeLa cells, both elements retrotransposed into a variety of chromosomal locations at a high frequency. The retrotransposed products resembled endogenous L1 insertions, since they were variably 5' truncated, ended in poly(A) tracts, and were flanked by target-site duplications or short deletions. Point mutations in conserved domains of the L1.2-encoded proteins reduced retrotransposition by 100- to 1000-fold. Remarkably, L1.2 also retrotransposed in a mouse cell line, suggesting a potential role for L1-based vectors in random insertional mutagenesis.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.